1887

Abstract

Cyclin-dependent protein kinases (CDKs) are important regulators of cellular processes and are functionally integrated into the replication of human cytomegalovirus (HCMV). Recently, a regulatory impact of CDK activity on the viral mRNA export factor pUL69 was shown. Here, specific aspects of the mode of interaction between CDK9/cyclin T1 and pUL69 are described. Intracellular localization was studied in the presence of a novel selective CDK9 inhibitor, R22, which exerts anti-cytomegaloviral activity . A pronounced R22-induced formation of nuclear speckled aggregation of pUL69 was demonstrated. Multi-labelling confocal laser-scanning microscopy revealed that CDK9 and cyclin T1 co-localized perfectly with pUL69 in individual speckles. The effects were similar to those described recently for the broad CDK inhibitor roscovitine. Co-immunoprecipitation and yeast two-hybrid analyses showed that cyclin T1 interacted with both CDK9 and pUL69. The interaction region of pUL69 for cyclin T1 could be attributed to aa 269–487. Moreover, another component of CDK inhibitor-induced speckled aggregates was identified with RNA polymerase II, supporting earlier reports that strongly suggested an association of pUL69 with transcription complexes. Interestingly, when using a UL69-deleted recombinant HCMV, no speckled aggregates were formed by CDK inhibitor treatment. This indicated that pUL69 is the defining component of aggregates and generally may represent a crucial viral interactor of cyclin T1. In conclusion, these data emphasize that HCMV inter-regulation with CDK9/cyclin T1 is at least partly based on a pUL69–cylin T1 interaction, thus contributing to the importance of CDK9 for HCMV replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.030494-0
2011-07-01
2019-10-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/7/1519.html?itemId=/content/journal/jgv/10.1099/vir.0.030494-0&mimeType=html&fmt=ahah

References

  1. Bain M. , Sinclair J. . ( 2007; ). The S phase of the cell cycle and its perturbation by human cytomegalovirus. . Rev Med Virol 17:, 423–434. [CrossRef].[PubMed].
    [Google Scholar]
  2. Biglione S. , Byers S. A. , Price J. P. , Nguyen V. T. , Bensaude O. , Price D. H. , Maury W. . ( 2007; ). Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. . Retrovirology 4:, 47. [CrossRef].[PubMed].
    [Google Scholar]
  3. Borst E. M. , Hahn G. , Koszinowski U. H. , Messerle M. . ( 1999; ). Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. . J Virol 73:, 8320–8329.[PubMed].
    [Google Scholar]
  4. Bresnahan W. A. , Boldogh I. , Chi P. , Thompson E. A. , Albrecht T. . ( 1997; ). Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. . Virology 231:, 239–247. [CrossRef].[PubMed].
    [Google Scholar]
  5. Chan G. , Nogalski M. T. , Yurochko A. D. . ( 2009; ). Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. . Proc Natl Acad Sci U S A 106:, 22369–22374. [CrossRef].[PubMed].
    [Google Scholar]
  6. Cheng Y.-C. , Prusoff W. H. . ( 1973; ). Relationship between the inhibition constant (KI ) and the concentration of inhibitor which causes 50 per cent inhibition (I 50) of an enzymatic reaction. . Biochem Pharmacol 22:, 3099–3108. [CrossRef].[PubMed].
    [Google Scholar]
  7. Dai-Ju J. Q. , Li L. , Johnson L. A. , Sandri-Goldin R. M. . ( 2006; ). ICP27 interacts with the C-terminal domain of RNA polymerase II and facilitates its recruitment to herpes simplex virus 1 transcription sites, where it undergoes proteasomal degradation during infection. . J Virol 80:, 3567–3581. [CrossRef].[PubMed].
    [Google Scholar]
  8. Datsenko K. A. , Wanner B. L. . ( 2000; ). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. . Proc Natl Acad Sci U S A 97:, 6640–6645. [CrossRef].[PubMed].
    [Google Scholar]
  9. Davido D. J. , von Zagorski W. F. , Maul G. G. , Schaffer P. A. . ( 2003; ). The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0. . J Virol 77:, 12603–12616. [CrossRef].[PubMed].
    [Google Scholar]
  10. De Azevedo W. F. , Leclerc S. , Meijer L. , Havlicek L. , Strnad M. , Kim S.-H. . ( 1997; ). Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. . Eur J Biochem 243:, 518–526. [CrossRef].[PubMed].
    [Google Scholar]
  11. de la Fuente C. , Maddukuri A. , Kehn K. , Baylor S. Y. , Deng L. , Pumfery A. , Kashanchi F. . ( 2003; ). Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. . Curr HIV Res 1:, 131–152. [CrossRef].[PubMed].
    [Google Scholar]
  12. Diwan P. , Lacasse J. J. , Schang L. M. . ( 2004; ). Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. . J Virol 78:, 9352–9365. [CrossRef].[PubMed].
    [Google Scholar]
  13. Durfee T. , Becherer K. , Chen P. L. , Yeh S. H. , Yang Y. , Kilburn A. E. , Lee W. H. , Elledge S. J. . ( 1993; ). The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. . Genes Dev 7:, 555–569. [CrossRef].[PubMed].
    [Google Scholar]
  14. Fields S. , Song O. . ( 1989; ). A novel genetic system to detect protein–protein interactions. . Nature 340:, 245–246. [CrossRef].[PubMed].
    [Google Scholar]
  15. Fischer P. M. , Gianella-Borradori A. . ( 2003; ). CDK inhibitors in clinical development for the treatment of cancer. . Expert Opin Investig Drugs 12:, 955–970. [CrossRef].[PubMed].
    [Google Scholar]
  16. Fortunato E. A. , McElroy A. K. , Sanchez I. , Spector D. H. . ( 2000; ). Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. . Trends Microbiol 8:, 111–119. [CrossRef].[PubMed].
    [Google Scholar]
  17. Hardcastle I. R. , Golding B. T. , Griffin R. J. . ( 2002; ). Designing inhibitors of cyclin-dependent kinases. . Annu Rev Pharmacol Toxicol 42:, 325–348. [CrossRef].[PubMed].
    [Google Scholar]
  18. Hayashi M. L. , Blankenship C. , Shenk T. . ( 2000; ). Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. . Proc Natl Acad Sci U S A 97:, 2692–2696. [CrossRef].[PubMed].
    [Google Scholar]
  19. Herget T. , Marschall M. . ( 2006; ). Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors. . In New Concepts of Antiviral Therapy, pp. 351–371. Edited by Holzenburg A. , Bogner E. . . London:: Springer;. [CrossRef].
    [Google Scholar]
  20. Herget T. , Freitag M. , Morbitzer M. , Kupfer R. , Stamminger T. , Marschall M. . ( 2004; ). Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. . Antimicrob Agents Chemother 48:, 4154–4162. [CrossRef].[PubMed].
    [Google Scholar]
  21. Hofmann H. , Flöss S. , Stamminger T. . ( 2000; ). Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. . J Virol 74:, 2510–2524. [CrossRef].[PubMed].
    [Google Scholar]
  22. Isaacson M. K. , Feire A. L. , Compton T. . ( 2007; ). Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. . J Virol 81:, 6241–6247. [CrossRef].[PubMed].
    [Google Scholar]
  23. Jault F. M. , Jault J. M. , Ruchti F. , Fortunato E. A. , Clark C. , Corbeil J. , Richman D. D. , Spector D. H. . ( 1995; ). Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. . J Virol 69:, 6697–6704.[PubMed].
    [Google Scholar]
  24. Kapasi A. J. , Spector D. H. . ( 2008; ). Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. . J Virol 82:, 394–407. [CrossRef].[PubMed].
    [Google Scholar]
  25. Kapasi A. J. , Clark C. L. , Tran K. , Spector D. H. . ( 2009; ). Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription. . J Virol 83:, 5904–5917. [CrossRef].[PubMed].
    [Google Scholar]
  26. Knockaert M. , Greengard P. , Meijer L. . ( 2002; ). Pharmacological inhibitors of cyclin-dependent kinases. . Trends Pharmacol Sci 23:, 417–425. [CrossRef].[PubMed].
    [Google Scholar]
  27. Kudoh A. , Fujita M. , Kiyono T. , Kuzushima K. , Sugaya Y. , Izuta S. , Nishiyama Y. , Tsurumi T. . ( 2003; ). Reactivation of lytic replication from B cells latently infected with Epstein–Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. . J Virol 77:, 851–861. [CrossRef].[PubMed].
    [Google Scholar]
  28. Kudoh A. , Daikoku T. , Sugaya Y. , Isomura H. , Fujita M. , Kiyono T. , Nishiyama Y. , Tsurumi T. . ( 2004; ). Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein–Barr virus immediate-early and early genes, preventing viral lytic replication. . J Virol 78:, 104–115. [CrossRef].[PubMed].
    [Google Scholar]
  29. Le V. T. , Trilling M. , Wilborn M. , Hengel H. , Zimmermann A. . ( 2008; ). Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. . J Gen Virol 89:, 2416–2426. [CrossRef].[PubMed].
    [Google Scholar]
  30. Lischka P. , Rosorius O. , Trommer E. , Stamminger T. . ( 2001; ). A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. . EMBO J 20:, 7271–7283. [CrossRef].[PubMed].
    [Google Scholar]
  31. Lischka P. , Toth Z. , Thomas M. , Mueller R. , Stamminger T. . ( 2006; ). The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-Box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA. . Mol Cell Biol 26:, 1631–1643. [CrossRef].[PubMed].
    [Google Scholar]
  32. Lu M. , Shenk T. . ( 1999; ). Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle. . J Virol 73:, 676–683.[PubMed].
    [Google Scholar]
  33. Majello B. , Napolitano G. . ( 2001; ). Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. . Front Biosci 6:, D1358–D1368. [CrossRef].[PubMed].
    [Google Scholar]
  34. Marschall M. , Stamminger T. . ( 2009; ). Molecular targets for antiviral therapy of cytomegalovirus infections. . Future Microbiol 4:, 731–742. [CrossRef].[PubMed].
    [Google Scholar]
  35. Marschall M. , Freitag M. , Weiler S. , Sorg G. , Stamminger T. . ( 2000; ). Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. . Antimicrob Agents Chemother 44:, 1588–1597. [CrossRef].[PubMed].
    [Google Scholar]
  36. Marschall M. , Feichtinger S. , Milbradt J. . ( 2011; ). Regulatory roles of protein kinases in cytomegalovirus replication. . Adv Virus Res (in press).
    [Google Scholar]
  37. Meinhart A. , Kamenski T. , Hoeppner S. , Baumli S. , Cramer P. . ( 2005; ). A structural perspective of CTD function. . Genes Dev 19:, 1401–1415. [CrossRef].[PubMed].
    [Google Scholar]
  38. Mett H. , Hölscher K. , Degen H. , Esdar C. , De Neumann B. F. , Flicke B. , Freudenreich T. , Holzer G. , Schinzel S. et al. ( 2005; ). Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay. . J Biomol Screen 10:, 36–45. [CrossRef].[PubMed].
    [Google Scholar]
  39. Mocarski E. S. Jr , Shenk T. , Pass R. F. . ( 2007; ). Cytomegalovirus. . In Fields Virology, , 5th edn., pp. 2701–2772. Edited by Knipe M. , Howley P. M. . . Philadelphia, PA:: Lippincott Williams & Wilkins;.
    [Google Scholar]
  40. Napolitano G. , Licciardo P. , Carbone R. , Majello B. , Lania L. . ( 2002; ). CDK9 has the intrinsic property to shuttle between nucleus and cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear localization. . J Cell Physiol 192:, 209–215. [CrossRef].[PubMed].
    [Google Scholar]
  41. Pumfery A. , de la Fuente C. , Berro R. , Nekhai S. , Kashanchi F. , Chao S. H. . ( 2006; ). Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. . Curr Pharm Des 12:, 1949–1961. [CrossRef].[PubMed].
    [Google Scholar]
  42. Rechter S. , Scott G. M. , Eickhoff J. , Zielke K. , Auerochs S. , Müller R. , Stamminger T. , Rawlinson W. D. , Marschall M. . ( 2009; ). Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. . J Biol Chem 284:, 8605–8613. [CrossRef].[PubMed].
    [Google Scholar]
  43. Reinberg D. , Orphanides G. , Ebright R. , Akoulitchev S. , Carcamo J. , Cho H. , Cortes P. , Drapkin R. , Flores O. et al. ( 1998; ). The RNA polymerase II general transcription factors: past, present, and future. . Cold Spring Harb Symp Quant Biol 63:, 83–103. [CrossRef].[PubMed].
    [Google Scholar]
  44. Salvant B. S. , Fortunato E. A. , Spector D. H. . ( 1998; ). Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. . J Virol 72:, 3729–3741.[PubMed].
    [Google Scholar]
  45. Sanchez V. , Spector D. H. . ( 2006; ). Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. . J Virol 80:, 5886–5896. [CrossRef].[PubMed].
    [Google Scholar]
  46. Sanchez V. , McElroy A. K. , Spector D. H. . ( 2003; ). Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. . J Virol 77:, 13214–13224. [CrossRef].[PubMed].
    [Google Scholar]
  47. Sanchez V. , McElroy A. K. , Yen J. , Tamrakar S. , Clark C. L. , Schwartz R. A. , Spector D. H. . ( 2004; ). Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122–123 and UL37 immediate-early transcripts and at later times for virus production. . J Virol 78:, 11219–11232. [CrossRef].[PubMed].
    [Google Scholar]
  48. Schang L. M. . ( 2002; ). Cyclin-dependent kinases as cellular targets for antiviral drugs. . J Antimicrob Chemother 50:, 779–792. [CrossRef].[PubMed].
    [Google Scholar]
  49. Schang L. M. . ( 2005; a). Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. . Curr Drug Targets Infect Disord 5:, 29–37. [CrossRef].[PubMed].
    [Google Scholar]
  50. Schang L. M. . ( 2005; b). Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science. . Expert Rev Anti Infect Ther 3:, 145–149. [CrossRef].[PubMed].
    [Google Scholar]
  51. Schang L. M. , St Vincent M. R. , Lacasse J. J. . ( 2006; ). Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. . Antivir Chem Chemother 17:, 293–320.[PubMed].[CrossRef]
    [Google Scholar]
  52. Schregel V. , Auerochs S. , Jochmann R. , Maurer K. , Stamminger T. , Marschall M. . ( 2007; ). Mapping of a self-interaction domain of the cytomegalovirus protein kinase pUL97. . J Gen Virol 88:, 395–404. [CrossRef].[PubMed].
    [Google Scholar]
  53. Scott G. M. , Weinberg A. , Rawlinson W. D. , Chou S. . ( 2007; ). Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. . Antimicrob Agents Chemother 51:, 89–94. [CrossRef].[PubMed].
    [Google Scholar]
  54. Sportsman J. R. , Gaudet E. A. , Boge A. . ( 2004; ). Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. . Assay Drug Dev Technol 2:, 205–214. [CrossRef].[PubMed].
    [Google Scholar]
  55. Tamrakar S. , Kapasi A. J. , Spector D. H. . ( 2005; ). Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. . J Virol 79:, 15477–15493. [CrossRef].[PubMed].
    [Google Scholar]
  56. Tavalai N. , Kraiger M. , Kaiser N. , Stamminger T. . ( 2008; ). Insertion of an EYFP-pp71 (UL82) coding sequence into the human cytomegalovirus genome results in a recombinant virus with enhanced viral growth. . J Virol 82:, 10543–10555. [CrossRef].[PubMed].
    [Google Scholar]
  57. Thomas M. , Rechter S. , Milbradt J. , Auerochs S. , Müller R. , Stamminger T. , Marschall M. . ( 2009; ). Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. . J Gen Virol 90:, 567–578. [CrossRef].[PubMed].
    [Google Scholar]
  58. Toth Z. , Lischka P. , Stamminger T. . ( 2006; ). RNA-binding of the human cytomegalovirus transactivator protein UL69, mediated by arginine-rich motifs, is not required for nuclear export of unspliced RNA. . Nucleic Acids Res 34:, 1237–1249. [CrossRef].[PubMed].
    [Google Scholar]
  59. Wang D. , de la Fuente C. , Deng L. , Wang L. , Zilberman I. , Eadie C. , Healey M. , Stein D. , Denny T. et al. ( 2001; ). Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. . J Virol 75:, 7266–7279. [CrossRef].[PubMed].
    [Google Scholar]
  60. Winkler M. , Stamminger T. . ( 1996; ). A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. . J Virol 70:, 8984–8987.[PubMed].
    [Google Scholar]
  61. Winkler M. , Rice S. A. , Stamminger T. . ( 1994; ). UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression. . J Virol 68:, 3943–3954.[PubMed].
    [Google Scholar]
  62. Yang Z. , He N. , Zhou Q. . ( 2008; ). Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. . Mol Cell Biol 28:, 967–976. [CrossRef].[PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.030494-0
Loading
/content/journal/jgv/10.1099/vir.0.030494-0
Loading

Data & Media loading...

vol. , part 7, pp. 1519 - 1531

CoIP analysis confirming the interaction between cyclin T1 (cytT1) and pUL69 [PDF](90 KB)



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error